Cytokine abnormalities in the etiology of the cardiometabolic syndrome

Current Hypertension Reports

Volumn 12, Issue 2, 2010, Pages 93-98

  DeMarco, Vincent G ^a   Johnson, Megan S ^a   Whaley Connell, Adam T ^a   Sowers, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Adipokines; CMS; Hypertension; Insulin resistance; Metabolic syndrome; Oxidative stress

Indexed keywords

ADIPOCYTOKINE; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; GLUCOSE; INSULIN SENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; BARIATRIC SURGERY; CARDIOMETABOLIC SYDROME; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENZYME DEFECT; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPID STORAGE; METABOLIC SYNDROME X; PROTEINURIA; REVIEW; RISK FACTOR;

ADIPOKINES; CYTOKINES; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MACROPHAGES; METABOLIC SYNDROME X; NADPH OXIDASE; OXIDATIVE STRESS; PROTEINURIA; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 77953526803     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0095-5     Document Type: Review

References (54)

1. Whaley-Connell A., Sowers JR: Hypertension and insulin resistance. Hypertension 2009, 54(3):462-464.
2. Sowers JR: Metabolic risk factors and renal disease. Kidney Int 2007, 71(8):719-720.
3. Kurukulasuriya LR, Stas S., Lastra G., et al.: Hypertension in obesity. Endocrinol Metab Clin North Am 2008, 37(3):647-662.
4. Whaley-Connell A., Sowers JR: Obesity, insulin resistance, and nocturnal systolic blood pressure. Hypertension 2008, 51(3):620-621.
5. Govindarajan G, Whaley-Connell A, Mugo M., et al.: The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 2005, 330:311-318.
6. Alberti KG, Eckel RH, Grundy S.M., et al.: Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
7. Wei Y, Chen K., Whaley-Connell AT, et al.: Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 2008, 294(3):R673-R680.
8. Sowers JR: Endocrine functions of adipose tissue; focus on adiponectin. Clin Cornerstone 2008, 9(1):32-38.
9. Cnop M, Havel PJ, Utzschneider K.M., et al.: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
10. Cano P, Cardinali DP, Rios-Lugo MJ, et al.: Effect of a high-fat diet on 24-hour pattern of circulating adipocytokines in rats. Obesity (Silver Spring) 2009, 17:1866-1871.
11. Berg AH, Combs TP, Du X., et al: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
12. Fruebis J, Tsao TS, Javorschi S., et al: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005-2010.
13. Matsubara M, Maruoka S., Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002, 147:173-180.
14. Arita Y, Kihara S., Ouchi N., et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
15. Yamauchi T, Kamon J., Waki H., et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
16. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
17. Uysal KT, Wiesbrock SM, Marino M.W., Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
18. Kubota N, Terauchi Y., Yamauchi T., et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866.
19. Hara K, Boutin P., Mori Y., et al.: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51:536-540.
20. Kondo H, Shimomura I., Matsukawa Y., et al.: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51:2325-2328.
21. Li S, Shin HJ, Ding E.L., van Dam RM: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
22. Furukawa S, Fujita T., Shimabukuro M., et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
23. Gaster M, Staehr P., Beck-Nielsen H, et al.: GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: Is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes 2001, 50:1324-1329.
24. Daugaard JR, Richter EA: Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus. Acta Physiol Scand 2001, 171:267-276.
25. Wei Y, Sowers JR, Nistala R., et al: Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006, 281:35137-35146.
26. Kamei N, Tobe K., Suzuki R., et al.: Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281:26602-26614.
27. Xu H, Barnes GT, Yang Q., et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
28. Weisberg SP, McCann D., Desai M., et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
29. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184.
30. Cancello R Tordjman J, Poitou C, et al.: Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006, 55:1554-1561.
31. Suganami T, Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005, 25:2062-2068.
32. Feuerer M, Herrero L., Cipolletta D., et al.: Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 15:930-939.
33. Greenstein AS, Khavandi K., Withers S.B., et al.: Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009, 119:1661-1670.
34. Grill HJ, Kaplan JM: The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002, 23:2-40.
35. Shi P, Raizada MK, Sumners C: Brain cytokines as neuromodulators in cardiovascular control. Clin Exp Pharmacol Physiol 2010, 37(2):e52-57.
36. Hausberg M, Morgan DA, Chapleau M.A., et al.: Differential modulation of leptin-induced sympathoexcitation by baroreflex activation. J Hypertens 2002, 20:1633-1641.
37. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R: Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol 2007, 58:591-610.
38. Psilopanagioti A, Papadaki H., Kranioti E.F., et al.: Expression of adiponectin and adiponectin receptors in human pituitary gland and brain. Neuroendocrinology 2009, 89:38-47.
39. Ahima RS, Lazar MA: Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 2008, 22:1023-1031.
40. Shimomura I, Hammer RE, Ikemoto S., et al: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73-76.
41. Jensen DR, Schlaepfer IR, Morin C.L., et al.: Prevention of dietinduced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am J Physiol 1997, 273:R683-R689.
42. Stevens VJ, Obarzanek E., Cook N.R., et al.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1-11.
43. Ziccardi P, Nappo F., Giugliano G., et al.: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.
44. Abate N, Garg A., Peshock R.M., et al.: Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995, 96:88-98.
45. Bobbert T, Rochlitz H., Wegewitz U., et al.: Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005, 54:2712-2719.
46. Yang WS, Lee WJ, Funahashi T., et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86:3815-3819.
47. Goldfine AB, Shoelson SE, Aguirre V: Expansion and contraction: treating diabetes with bariatric surgery. Nat Med 2009, 15:616-617.
48. Buchwald H, Estok R., Fahrbach K., et al.: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.
49. Moschen AR, Molnar C., Wolf A.M., et al.: Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009, 51:765-777.
50. Araki K, Masaki T., Katsuragi I., et al.: Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 2008, 16:2068-2073.
51. Combs TP, Wagner JA, Berger J., et al: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002, 143:998-1007.
52. Hansmann G, Wagner RA, Schellong S., et al: Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation. Circulation 2007, 115(10):1275-1284.
53. Mohapatra J, Sharma M., Singh S., et al.: Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. Pharmacology 2009, 84:203-210.
54. McCall KL, Craddock D., Edwards K: Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006, 26:1297-1306.